The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy

Joanne N Davis, Clinton Medbery 3rd, Sanjeev Sharma, Adnan Danish, Anand Mahadevan, Joanne N Davis, Clinton Medbery 3rd, Sanjeev Sharma, Adnan Danish, Anand Mahadevan

Abstract

Background: The RSSearch™ Registry is a multi-institutional, observational, ongoing registry established to standardize data collection from patients treated with stereotactic radiosurgery (SRS) and/or stereotactic body radiotherapy (SBRT). This report describes the design, patient demographics, lesion characteristics, and SRS/SBRT treatment patterns in RSSearch™. Illustrative patient-related outcomes are also presented for two common treatment sites--brain metastases and liver metastases.

Materials and methods: Thirty-nine US centers participated in RSSearch™. Patients screened for SRS/SBRT were eligible to be enrolled. Descriptive analyses were performed to assess patient characteristics, physician treatment practices, and clinical outcomes. Kaplan-Meier analysis was used to determine overall survival (OS), local progression-free (LPFS), and distant disease-free survival (DDFS).

Results: From January, 2008-January, 2013, 11,457 patients were enrolled. The median age was 67 years (range 7-100 years); 51% male and 49% female. Forty-six percent had no prior treatment, 22% had received chemotherapy, 19% radiation therapy and 17% surgery. There were 11,820 lesions from 65 treatment locations; 54% extracranial and 46% intracranial. The most common treatment locations were brain/cranial nerve/spinal cord, lung, prostate and liver. Metastatic lesions accounted for the majority of cases (41.6%), followed by primary malignant (32.9%), benign (10.9%), recurrent (9.4%), and functional diseases (4.3%). SRS/SBRT was used with a curative intent in 39.8% and palliative care in 44.8% of cases. The median dose for all lesions was 30 Gy (range < 1-96.7 Gy) delivered in a median number of 3 fractions. The median dose for lesions in the brain/cranial nerve/spinal cord, lung, liver, pancreas and prostate was 24, 54, 45, 29 and 36.25 Gy, respectively. In a subset analysis of 799 patients with 952 brain metastases, median OS was 8 months. For patients with a Karnofsky performance score (KPS) > 70, OS was 11 months vs. 4 months for KPS ≤ 70. Six-month and 12-month local control was 79% and 61%, respectively for patients with KPS ≤ 70, and 85% and 74%, respectively for patients with KPS > 70. In a second subset analysis including 174 patients with 204 liver metastases, median OS was 22 months. At 1-year, LPFS and DDFS rates were 74% and 53%, respectively.

Lpfs conclusion: This study demonstrates that collective patterns of care and outcomes research for SRS/SBRT can be performed and reported from data entered by users in a common database. The RSSearch™ dataset represents SRS/SBRT practices in a real world setting, providing a useful resource for expanding knowledge of SRS/SBRT treatment patterns and outcomes and generating robust hypotheses for randomized clinical studies.

Figures

Figure 1
Figure 1
Location and percentage of intracranial lesions (A) and extracranial lesions (B) treated with SRS/SBRT.
Figure 2
Figure 2
Kaplan-Meier analysis of overall survival (A) and local control (B) of brain metastases treated with SRS. Patients with a baseline Karnofsky performance score (KPS) ≤ 70 are indicated by dotted line and patients with KPS > 70 are indicated by solid black line.
Figure 3
Figure 3
Kaplan-Meier analysis of overall survival (A) and local and distant progression-free survival (B) of hepatic metastases treated with SBRT.

References

    1. Flickinger JC, Kondziolka D. Radiosurgery instead of resection for solitary brain metastasis: the gold standard redefined. Int J Radiat Oncol Biol Phys. 1996;8:185–186.
    1. Flickinger JC, Lunsford LD, Somaza S, Kondziolka D. Radiosurgery: its role in brain metastasis management. Neurosurg Clin N Am. 1996;8:497–504.
    1. Kondziolka D, Lunsford LD, Flickinger JC, Young RF, Vermeulen S, Duma CM, Jacques DB, Rand RW, Regis J, Peragut JC. et al.Stereotactic radiosurgery for trigeminal neuralgia: a multiinstitutional study using the gamma unit. J Neurosurg. 1996;8:940–945. doi: 10.3171/jns.1996.84.6.0940.
    1. Leksell L. Sterotaxic radiosurgery in trigeminal neuralgia. Acta Chir Scand. 1971;8:311–314.
    1. Larsson B, Liden K, Sarby B. Irradiation of small structures through the intact skull. Acta Radiol Ther Phys Biol. 1974;8:512–534.
    1. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;8:797–803. doi: 10.1136/jnnp.46.9.797.
    1. Betti OO, Galmarini D, Derechinsky V. Radiosurgery with a linear accelerator. Methodological aspects. Stereotact Funct Neurosurg. 1991;8:87–98. doi: 10.1159/000099559.
    1. Lee JY, Niranjan A, McInerney J, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg. 2002;8:65–72. doi: 10.3171/jns.2002.97.1.0065.
    1. Roos DE, Potter AE, Brophy BP. Stereotactic radiosurgery for acoustic neuromas: what happens long term? Int J Radiat Oncol Biol Phys. 2012;8:1352–1355. doi: 10.1016/j.ijrobp.2011.04.068.
    1. Kong DS, Lee JI, Lim do H, Kim KW, Shin HJ, Nam DH, Park K, Kim JH. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer. 2007;8:854–860. doi: 10.1002/cncr.22860.
    1. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;8:861–870. doi: 10.3109/02841869509127197.
    1. Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A, Schlegel W, Wannenmacher MF. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000;8:329–335. doi: 10.1016/S0360-3016(99)00413-7.
    1. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;8:1946–1955. doi: 10.1378/chest.124.5.1946.
    1. Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM Jr, Rodebaugh R, Weinhous MS, Le QT. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;8:1097–1101. doi: 10.1016/S0003-4975(02)04681-7.
    1. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S. et al.Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8:58. doi: 10.1186/1748-717X-8-58.
    1. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;8:3. doi: 10.1186/1748-717X-6-3.
    1. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;8:1588–1597. doi: 10.1016/j.ijrobp.2007.11.067.
    1. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;8:1. doi: 10.1186/1471-2490-10-1.
    1. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118. doi: 10.1186/1748-717X-8-118.
    1. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;8:48–53. doi: 10.1016/j.radonc.2004.12.022.
    1. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;8:320–323. doi: 10.1016/j.ijrobp.2005.07.002.
    1. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK. et al.Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;8:1017–1021. doi: 10.1016/j.ijrobp.2003.11.004.
    1. Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;8:735–742. doi: 10.1016/j.ijrobp.2009.08.046.
    1. Comet B, Kramar A, Faivre-Pierret M, Dewas S, Coche-Dequeant B, Degardin M, Lefebvre JL, Lacornerie T, Lartigau EF. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;8:203–209. doi: 10.1016/j.ijrobp.2011.11.054.
    1. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT. et al.Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;8:1493–1500. doi: 10.1016/j.ijrobp.2008.12.075.
    1. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2009;8:1047–1053. doi: 10.1016/j.ijrobp.2008.09.022.
    1. Svedman C, Karlsson K, Rutkowska E, Sandstrom P, Blomgren H, Lax I, Wersall P. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;8:1578–1583. doi: 10.1080/02841860802123196.
    1. Bondiau PY, Courdi A, Bahadoran P, Chamorey E, Queille-Roussel C, Lallement M, Birtwisle-Peyrottes I, Chapellier C, Pacquelet-Cheli S, Ferrero JM. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013;8:1193–1199. doi: 10.1016/j.ijrobp.2012.10.034.
    1. Haas JA, Witten MR, Clancey O, Episcopia K, Accordino D, Chalas E. CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy. Front Oncol. 2012;8:25.
    1. Higginson DS, Morris DE, Jones EL, Clarke-Pearson D, Varia MA. Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology. Gynecol Oncol. 2011;8:404–412. doi: 10.1016/j.ygyno.2010.11.042.
    1. Kemmerer E, Hernandez E, Ferriss JS, Valakh V, Miyamoto C, Li S, Micaily B. Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. Int J Radiat Oncol Biol Phys. 2013;8:129–135. doi: 10.1016/j.ijrobp.2012.02.058.
    1. Gliklich RE, Dreyer NA. Registries for Evaluating Patient Outcomes: A User's Guide (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under contract No. HHSA29020050035ITO1. AHRQ Publication No. 07-EHC001-1; 2010.
    1. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;8:2155–2161. doi: 10.1200/JCO.2007.14.5631.
    1. Shahian DM, Jacobs JP, Edwards FH, Brennan JM, Dokholyan RS, Prager RL, Wright CD, Peterson ED, McDonald DE, Grover FL. The society of thoracic surgeons national database. Heart. 2013;8:1494–1501. doi: 10.1136/heartjnl-2012-303456.
    1. Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB. et al.First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005;8:1138–1148. doi: 10.1002/cncr.21289.
    1. The Radiosurgery Society. .
    1. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP. et al.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;8:1665–1672. doi: 10.1016/S0140-6736(04)16250-8.
    1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H. et al.Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;8:2483–2491. doi: 10.1001/jama.295.21.2483.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;8:427–434.
    1. Rades D, Pluemer A, Veninga T, Hanssens P, Dunst J, Schild SE. Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer. 2007;8:2285–2292. doi: 10.1002/cncr.23037.
    1. Weintraub WS, Grau-Sepulveda MV, Weiss JM, O'Brien SM, Peterson ED, Kolm P, Zhang Z, Klein LW, Shaw RE, McKay C. et al.Comparative effectiveness of revascularization strategies. N Engl J Med. 2012;8:1467–1476. doi: 10.1056/NEJMoa1110717.
    1. DiBardino DJ, Pasquali SK, Hirsch JC, Benjamin DK, Kleeman KC, Salazar JD, Jacobs ML, Mayer JE, Jacobs JP. Effect of sex and race on outcome in patients undergoing congenital heart surgery: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg. 2012;8:2054–2059. doi: 10.1016/j.athoracsur.2012.05.124. discussion 2059–60.
    1. Rankin JS, He X, O'Brien SM, Jacobs JP, Welke KF, Filardo G, Shahian DM. The Society of Thoracic Surgeons risk model for operative mortality after multiple valve surgery. Ann Thorac Surg. 2013;8:1484–1490. doi: 10.1016/j.athoracsur.2012.11.077.
    1. Haffty BG, Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer H. et al.Timing of Chemotherapy after MammoSite radiation therapy system breast brachytherapy: analysis of the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. Int J Radiat Oncol Biol Phys. 2008;8:1441–1448. doi: 10.1016/j.ijrobp.2008.02.070.
    1. Vicini F, Beitsch PD, Quiet CA, Keleher AJ, Garcia D, Snider HC Jr, Gittleman MA, Zannis VJ, Kuerer HM, Lyden M. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI) Cancer. 2008;8:758–766. doi: 10.1002/cncr.23227.
    1. Jeruss JS, Kuerer HM, Beitsch PD, Vicini FA, Keisch M. Update on DCIS outcomes from the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. Ann Surg Oncol. 2011;8:65–71. doi: 10.1245/s10434-010-1192-z.
    1. Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S, Lyden M, Haffty BG. Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial. Ann Surg Oncol. 2012;8:1477–1483. doi: 10.1245/s10434-011-2133-1.
    1. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys. 2000;8:291–298. doi: 10.1016/S0360-3016(99)00507-6.
    1. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;8:37–46. doi: 10.1016/j.ijrobp.2005.05.023.
    1. Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, Regine WF, Weltman E, King VJ, Goetsch SJ. et al.Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;8:426–434. doi: 10.1016/S0360-3016(01)01622-4.
    1. Li B, Yu J, Suntharalingam M, Kennedy AS, Amin PP, Chen Z, Yin R, Guo S, Han T, Wang Y. et al.Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer. 2000;8:37–45. doi: 10.1002/(SICI)1097-0215(20000220)90:1<37::AID-IJC5>;2-7.
    1. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;8:745–751. doi: 10.1016/S0360-3016(96)00619-0.
    1. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L. et al.Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;8:4078–4101. doi: 10.1118/1.3438081.
    1. Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011;8:3368.
    1. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;8:215–222. doi: 10.1016/j.semradonc.2008.04.001.
    1. Lock MI, Hoyer M, Bydder SA, Okunieff P, Hahn CA, Vichare A, Dawson LA. An international survey on liver metastases radiotherapy. Acta Oncol. 2012;8:568–574. doi: 10.3109/0284186X.2012.681700.
    1. Habermehl D, Herfarth KK, Bermejo JL, Hof H, Rieken S, Kuhn S, Welzel T, Debus J, Combs SE. Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol. 2013;8:175. doi: 10.1186/1748-717X-8-175.
    1. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;8:4060–4069. doi: 10.1002/cncr.25997.
    1. Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, Schoelles KM. Stereotactic Body Radiation Therapy [Internet]. Stereotactic Body Radiation Therapy [Internet] Rockville, MD: Agency for Healthcare Research and Quality (US); 2011. (Comparative Effectiveness Technical Briefs, No. 6.) Available from:
    1. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N. et al.Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;8:1427–1431. doi: 10.1016/j.ijrobp.2005.05.034.
    1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D. et al.Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;8:1070–1076. doi: 10.1001/jama.2010.261.
    1. Fritz P, Kraus HJ, Blaschke T, Muhlnickel W, Strauch K, Engel-Riedel W, Chemaissani A, Stoelben E. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer. 2008;8:193–199. doi: 10.1016/j.lungcan.2007.10.005.
    1. Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;8:435–442. doi: 10.1016/j.radonc.2007.10.044.
    1. Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC) Cancer. 2007;8:148–155. doi: 10.1002/cncr.22763.
    1. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;8:967–971. doi: 10.1016/j.ijrobp.2008.08.001.
    1. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;8:1010–1015. doi: 10.1016/j.ijrobp.2005.03.073.
    1. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y. et al.Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;8:S94–S100. doi: 10.1097/JTO.0b013e318074de34.
    1. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;8:877–882. doi: 10.1016/j.ijrobp.2010.11.054.
    1. American Society of Therapeutic Radiation Oncology Model Policies. Stereotactic Body Radiation Therapy. 2013. Accessed in September 2013, Available at .
    1. Heinzerling JH, Bland R, Mansour JC, Schwarz RE, Ramirez E, Ding C, Abdulrahman R, Boike TP, Solberg T, Timmerman RD, Meyer JJ. Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiat Oncol. 2011;8:146. doi: 10.1186/1748-717X-6-146.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe